A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
about
Paroxysmal nocturnal hemoglobinuria from bench to bedsideDesign and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseasesAlternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous NephropathyTherapeutic regulation of complement in patients with renal disease - where is the promise?Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome.A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degenerationCan cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?Review: Complement and its regulatory proteins in kidney diseases.Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation.Role of ocular complement factor H in a murine model of choroidal neovascularization.Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in miceEpithelial cell-specific MyD88 signaling mediates ischemia/reperfusion-induced intestinal injury independent of microbial status.Complement inhibition alleviates paraquat-induced acute lung injury.Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a new translational model.Complement control protein factor H: the good, the bad, and the inadequate.Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure.Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injuryA novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.Complement System Part I - Molecular Mechanisms of Activation and Regulation.Inhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responsesTargeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injuryIL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cellsAccess to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation.Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency.Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitisThe alternative complement pathway propagates inflammation and injury in murine ischemic strokeTargeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complementProgress and Trends in Complement TherapeuticsComplement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in miceA new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor.Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular InjuryThe role of the immune response in age-related macular degeneration
P2860
Q24599629-DE92D03F-E902-48FB-BD98-8092FAB01A59Q24632001-90F7B6BA-67E0-4B6C-9516-DE2AE3728655Q26747416-C3E8371E-0332-460A-BA0A-F48FF1D7DFC5Q26851705-AF6C4EFF-C3A9-417A-882F-A6A077A14CFFQ33396528-0C960D08-57ED-4AB0-A6E9-C9A3558F6A95Q33415294-1595396B-D44E-40F3-8FCA-8BE4E9844420Q33636425-1ABABA57-A401-4B49-A144-67C6B780EE25Q33647738-09AB7370-6378-473D-9C2E-934E9C6CDA2EQ33652041-8FE3AA9F-F59B-47D4-BF5B-0701EB594689Q33683222-BEA90E59-9D50-443B-8D91-DE120BDFD156Q33687307-C2A9D0E9-6D43-4EB7-BC59-E04B193ADA4AQ33689251-3A33773F-03A1-4FFD-A689-0B07E01EA995Q33769308-70B6BF9B-7112-49CF-9B26-603170ED81C0Q33816347-FAE8F5D3-D5E3-4493-87F1-A6D445EBD987Q34067107-69751886-752C-43C7-A760-EC810E55CD82Q34070523-63C8DE1C-B11C-4D87-B4F4-1DED55CF484FQ34089200-4E58D451-689D-4958-8013-7398B67F3B9CQ34151843-A7C2C29E-371A-4224-93A7-4179C846478FQ34358170-A20AAD64-424F-4A79-9BA7-FAA4EF06F2EBQ34423372-47682DE6-04A4-4D7A-BD67-B91355BB0F98Q34481071-07ECF82E-CFAB-4E59-8983-091F01B5CB2DQ34624453-D78B49F5-4F72-47E0-8AB5-7A7E0E54A6BEQ34712205-F44CF441-D027-45B1-9B9E-29535E94F9BAQ34813568-8DDEBF4A-2800-46A9-A29D-5BABA42B0500Q35002158-0CD39270-36DC-40D7-AFE9-6ADC59E28D73Q35097512-686EAD23-3FB9-4DB9-895C-D49F3B345167Q35126751-AC90A11E-5855-4A9D-8A96-8976E18C5044Q35372492-FA6F733E-D6F3-4316-8682-C8BB08F2ADA1Q35659039-1AAC7B7E-2D30-4AF6-8B80-C82F503C9C80Q35864583-0AA5D6F0-BBFB-4576-87C1-470533C15E93Q36016468-079C483E-8907-44EB-A333-E559B986A1D1Q36339354-C01056FC-733C-4425-92FF-632C6BA95AD3Q36401237-CE98D19F-F50B-4FD0-8DAF-C27EAE89753EQ36417096-F06DD193-6AB1-48DA-B488-AD0E8BA4F25AQ36479278-AF56DA85-3567-4741-B13C-7D40ABE248C2Q36569510-4EC9D222-5E7E-430D-B9AD-93CE8C3A0F9EQ36572065-35B822F6-43C5-42A1-843E-496582E5B3FBQ36698228-4D0C6CD8-B799-4E0A-9762-AA6CF0B44028Q36791083-E3C35710-41D0-47F0-AEAD-F33512BEB2FEQ36914129-E1C87A83-D467-4602-B688-662D20D226D6
P2860
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@en
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@nl
type
label
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@en
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@nl
prefLabel
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@en
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@nl
P2093
P2860
P1476
A novel targeted inhibitor of ...... n ischemia/reperfusion injury.
@en
P2093
Carl Atkinson
Stephen Tomlinson
V Michael Holers
Yuxiang Huang
P2860
P304
P356
10.4049/JIMMUNOL.181.11.8068
P407
P577
2008-12-01T00:00:00Z